The increasing number of approved nucleic acid therapeutics demonstrates the potential to
treat diseases by targeting their genetic blueprints in vivo. Conventional treatments …

Antisense technology is now beginning to deliver on its promise to treat diseases by
targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing …

Recent medical advances have exploited the ability to address a given disease at the
underlying level of transcription and translation. These treatment paradigms utilize nucleic …

Apolipoproteins are important structural components of plasma lipoproteins that influence
vascular biology and atherosclerotic disease pathophysiology by regulating lipoprotein …

Abstract Aims Cardiac microRNA-132-3p (miR-132) levels are increased in patients with
heart failure (HF) and mechanistically drive cardiac remodelling processes. CDR132L, a …

Advances in biomaterials for drug delivery are enabling significant progress in biology and
medicine. Multidisciplinary collaborations between physical scientists, engineers, biologists …

Emerging therapeutics that utilize RNA interference (RNAi) have the potential to treat broad
classes of diseases due to their ability to reversibly silence target genes. In August 2018, the …

RNA-targeted therapies represent a platform for drug discovery involving chemically
modified oligonucleotides, a wide range of cellular RNAs, and a novel target-binding motif …

Material de distribuição exclusiva à classe médica. Os Arquivos Brasileiros de Cardiologia
não se responsabilizam pelo acesso indevido a seu conteúdo e que contrarie a …

Hyperlipidemia, defined as the presence of excess fat or lipids in the blood, has been
considered as a high-risk factor and key indicator of many metabolic diseases. The gut …